AU2016203567B2 — Novel gastro- retentive dosage forms comprising a GABA Analog and an opioid
Assigned to Gruenenthal GmbH · Expires 2017-12-07 · 8y expired
What this patent protects
NOVEL GASTRO- RETENTIVE DOSAGE FORMS COMPRISING A GABA ANALOG AND AN OPIOID The present invention provides a gastro-retentive pharmaceutical dosage form comprising a therapeutically effective amount of at least one GABA Analog, at least one opioid, and at least one pharmaceutical…
USPTO Abstract
NOVEL GASTRO- RETENTIVE DOSAGE FORMS COMPRISING A GABA ANALOG AND AN OPIOID The present invention provides a gastro-retentive pharmaceutical dosage form comprising a therapeutically effective amount of at least one GABA Analog, at least one opioid, and at least one pharmaceutically acceptable excipient wherein the said dosage form is retained in the stomach for at least four hours and is suitable for once daily or twice daily administration. The present invention further provides a method of treating a disorder by administering to a patient in need thereof, a gastro-retentive pharmaceutical dosage form comprising a therapeutically effective amount of at least one GABA Analog, at least one opioid, and at least one pharmaceutically acceptable excipient wherein the said dosage form is retained in the stomach for at least four hours and is suitable for once daily or twice daily administration. The said opioid is either in slow release form or in immediate release form.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.